Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TU-100 in Moderate Crohn's Disease
NCT01388933Phase 2Terminated
- Sponsor
- Tsumura & Co.
- Start
- Sep 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing TU-100 with Placebo (2 arms). Primary endpoint: Clinical response as measured by a reduction in the CDAI total score at 8 weeks. Started Sep 2011; status: terminated.
02
Drugs
daikenchuto
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01388933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01388933.